PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
44.36%
Net income growth above 1.5x CRWV's 7.67%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
No Data
No Data available this quarter, please select a different quarter.
15.07%
Well above CRWV's 3.70% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-410.05%
Both cut yoy SBC, with CRWV at -21.18%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-228.71%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-146.35%
Both yoy AR lines negative, with CRWV at -35.57%. Martin Whitman would suspect an overall sector lean approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-351.77%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
1438.60%
Well above CRWV's 23.14%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-20.53%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-28.08%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-1672.73%
Negative yoy acquisition while CRWV stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
29.82%
Purchases growth of 29.82% while CRWV is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-13.84%
Both yoy lines are negative, with CRWV at -100.00%. Martin Whitman suspects an environment prompting fewer sales or fewer maturities within the niche.
No Data
No Data available this quarter, please select a different quarter.
175.82%
We have mild expansions while CRWV is negative at -70.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-562.15%
Negative yoy issuance while CRWV is 4.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-77.42%
We cut yoy buybacks while CRWV is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.